IP Law

Vanda Schizophrenia Drug Patent Survives Appeals Court (1)

April 13, 2018, 3:56 PM; Updated: April 13, 2018, 8:47 PM

Vanda Pharmaceuticals Inc.’s patent relating to a treatment for schizophrenia is eligible for protection, a federal appeals court ruled.

The U.S. Court of Appeals for the Federal Circuit said April 13 that the patent, which relates to adjusting the dosage depending on the level of a particular enzyme activity in the patient, is not directed at an unpatentable law of nature. The court affirmed a lower court decision to block West-Ward Pharmaceuticals Corp.’s attempts to introduce a generic competing product.

The decision demonstrates how a patent can relate to a natural phenomenon but not run afoul of prohibitions against patenting...

To read the full article log in. To learn more about a subscription click here.